Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Novel Platforms for the Development of a Universal Influenza Vaccine.

Kumar A, Meldgaard TS, Bertholet S.

Front Immunol. 2018 Mar 23;9:600. doi: 10.3389/fimmu.2018.00600. eCollection 2018. Review.

2.

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Leroux-Roels G, Lattanzi M, Solis CD, Contorni M, Costantini M, Moraschini L, Bardelli M, Bertholet S, Borgogni E, Buricchi F, Cantisani R, Faenzi E, Finco O, Leuzzi R, Pizza M, Rosa D, Schiavetti F, Seubert A, Spensieri F, Volpini G, Zedda L, Giudice GD, Galgani I.

Hum Vaccin Immunother. 2018 Jan 2;14(1):45-58. doi: 10.1080/21645515.2017.1385686. Epub 2017 Nov 27.

3.

Staphylococcus aureus-dependent septic arthritis in murine knee joints: local immune response and beneficial effects of vaccination.

Corrado A, Donato P, Maccari S, Cecchi R, Spadafina T, Arcidiacono L, Tavarini S, Sammicheli C, Laera D, Manetti AG, Ruggiero P, Galletti B, Nuti S, De Gregorio E, Bertholet S, Seubert A, Bagnoli F, Bensi G, Chiarot E.

Sci Rep. 2016 Nov 30;6:38043. doi: 10.1038/srep38043.

4.

Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Magini D, Giovani C, Mangiavacchi S, Maccari S, Cecchi R, Ulmer JB, De Gregorio E, Geall AJ, Brazzoli M, Bertholet S.

PLoS One. 2016 Aug 15;11(8):e0161193. doi: 10.1371/journal.pone.0161193. eCollection 2016.

5.

Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans.

Spensieri F, Siena E, Borgogni E, Zedda L, Cantisani R, Chiappini N, Schiavetti F, Rosa D, Castellino F, Montomoli E, Bodinham CL, Lewis DJ, Medini D, Bertholet S, Del Giudice G.

PLoS One. 2016 Jun 23;11(6):e0157066. doi: 10.1371/journal.pone.0157066. eCollection 2016.

6.

Anticipating policy considerations for a future HIV vaccine: a preliminary study.

Williams EA, Lewis DJ, Bertholet S, Zazzi M.

Vaccine. 2016 Jul 12;34(32):3697-701. doi: 10.1016/j.vaccine.2016.03.086. Epub 2016 Apr 4.

PMID:
27055022
7.

Positive Contribution of Adjuvanted Influenza Vaccines to the Resolution of Bacterial Superinfections.

Zurli V, Gallotta M, Taccone M, Chiarot E, Brazzoli M, Corrente F, Bonci A, Casini D, De Gregorio E, Baudner BC, Bertholet S, Seubert A.

J Infect Dis. 2016 Jun 15;213(12):1876-85. doi: 10.1093/infdis/jiw048. Epub 2016 Feb 9.

PMID:
26908732
8.

One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.

Mancini F, Monaci E, Lofano G, Torre A, Bacconi M, Tavarini S, Sammicheli C, Arcidiacono L, Galletti B, Laera D, Pallaoro M, Tuscano G, Fontana MR, Bensi G, Grandi G, Rossi-Paccani S, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Soldaini E, Bertholet S.

PLoS One. 2016 Jan 26;11(1):e0147767. doi: 10.1371/journal.pone.0147767. eCollection 2016.

9.

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S.

J Virol. 2015 Oct 14;90(1):332-44. doi: 10.1128/JVI.01786-15. Print 2016 Jan 1.

10.

MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers.

Monaci E, Mancini F, Lofano G, Bacconi M, Tavarini S, Sammicheli C, Arcidiacono L, Giraldi M, Galletti B, Rossi Paccani S, Torre A, Fontana MR, Grandi G, de Gregorio E, Bensi G, Chiarot E, Nuti S, Bagnoli F, Soldaini E, Bertholet S.

Front Immunol. 2015 Sep 7;6:439. doi: 10.3389/fimmu.2015.00439. eCollection 2015.

11.

Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay.

Prevato M, Ferlenghi I, Bonci A, Uematsu Y, Anselmi G, Giusti F, Bertholet S, Legay F, Telford JL, Settembre EC, Maione D, Cozzi R.

PLoS One. 2015 Aug 17;10(8):e0135474. doi: 10.1371/journal.pone.0135474. eCollection 2015.

12.

An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.

Prevato M, Cozzi R, Pezzicoli A, Taddei AR, Ferlenghi I, Nandi A, Montomoli E, Settembre EC, Bertholet S, Bonci A, Legay F.

PLoS One. 2015 Aug 12;10(8):e0135383. doi: 10.1371/journal.pone.0135383. eCollection 2015.

13.

B Cells and Functional Antibody Responses to Combat Influenza.

Lofano G, Kumar A, Finco O, Del Giudice G, Bertholet S.

Front Immunol. 2015 Jun 30;6:336. doi: 10.3389/fimmu.2015.00336. eCollection 2015. Review.

14.

Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination.

Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, Tavarini S, Sammicheli C, Rossi Paccani S, Soldaini E, Laera D, Finco O, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Bertholet S.

J Immunol. 2015 Aug 15;195(4):1617-27. doi: 10.4049/jimmunol.1402604. Epub 2015 Jul 13.

15.

Innate Response Activator (IRA) B Cells Reside in Human Tonsils and Internalize Bacteria In Vitro.

Chiappini N, Cantisani R, Pancotto L, Ruggiero P, Rosa D, Manetti A, Romano A, Montagnani F, Bertholet S, Castellino F, Del Giudice G.

PLoS One. 2015 Jun 12;10(6):e0129879. doi: 10.1371/journal.pone.0129879. eCollection 2015.

16.

Gaps in knowledge and prospects for research of adjuvanted vaccines.

Seder R, Reed SG, O'Hagan D, Malyala P, D'Oro U, Laera D, Abrignani S, Cerundolo V, Steinman L, Bertholet S.

Vaccine. 2015 Jun 8;33 Suppl 2:B40-3. doi: 10.1016/j.vaccine.2015.03.057.

PMID:
26022566
17.

Four-component Staphylococcus aureus vaccine 4C-staph enhances Fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice.

Torre A, Bacconi M, Sammicheli C, Galletti B, Laera D, Fontana MR, Grandi G, De Gregorio E, Bagnoli F, Nuti S, Bertholet S, Bensi G.

Infect Immun. 2015 Aug;83(8):3157-63. doi: 10.1128/IAI.00258-15. Epub 2015 May 26.

18.

Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response to Staphylococcus aureus.

Pozzi C, Lofano G, Mancini F, Soldaini E, Speziale P, De Gregorio E, Rappuoli R, Bertholet S, Grandi G, Bagnoli F.

FEMS Microbiol Rev. 2015 Sep;39(5):750-63. doi: 10.1093/femsre/fuv024. Epub 2015 May 19. Review.

PMID:
25994610
19.

Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.

Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O'Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3680-5. doi: 10.1073/pnas.1424924112. Epub 2015 Mar 9.

20.

Evaluating the efficiency of isotope transmission for improved panel design and a comparison of the detection sensitivities of mass cytometer instruments.

Tricot S, Meyrand M, Sammicheli C, Elhmouzi-Younes J, Corneau A, Bertholet S, Malissen M, Le Grand R, Nuti S, Luche H, Cosma A.

Cytometry A. 2015 Apr;87(4):357-68. doi: 10.1002/cyto.a.22648. Epub 2015 Feb 20.

21.

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12294-9. doi: 10.1073/pnas.1400478111. Epub 2014 Aug 18. Review.

22.

Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.

Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A, Kommareddy S, Bertholet S, O'Hagan DT, Baudner BC.

Vaccine. 2014 Apr 25;32(20):2382-8. doi: 10.1016/j.vaccine.2013.12.043. Epub 2014 Jan 13.

PMID:
24434044
23.

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.

24.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

25.

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A.

Vaccine. 2013 Jul 18;31(33):3363-9. doi: 10.1016/j.vaccine.2013.05.007. Epub 2013 May 16.

PMID:
23684834
26.

Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

Peters NC, Bertholet S, Lawyer PG, Charmoy M, Romano A, Ribeiro-Gomes FL, Stamper LW, Sacks DL.

J Immunol. 2012 Nov 15;189(10):4832-41. doi: 10.4049/jimmunol.1201676. Epub 2012 Oct 8.

27.

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials.

Bagnoli F, Bertholet S, Grandi G.

Front Cell Infect Microbiol. 2012 Feb 22;2:16. doi: 10.3389/fcimb.2012.00016. eCollection 2012. Review. No abstract available.

28.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.

29.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.

PMID:
22425788
30.

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN.

J Immunol. 2012 Mar 1;188(5):2189-97. doi: 10.4049/jimmunol.1102696. Epub 2012 Jan 30.

31.

Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope.

Olugbile S, Villard V, Bertholet S, Jafarshad A, Kulangara C, Roussilhon C, Frank G, Agak GW, Felger I, Nebie I, Konate K, Kajava AV, Schuck P, Druilhe P, Spertini F, Corradin G.

Vaccine. 2011 Sep 16;29(40):7090-9. doi: 10.1016/j.vaccine.2011.06.122. Epub 2011 Jul 29.

32.

Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis.

Bertholet S, Horne DJ, Laughlin EM, Savlov M, Tucakovic I, Coler RN, Narita M, Reed SG.

Clin Vaccine Immunol. 2011 Aug;18(8):1378-86. doi: 10.1128/CVI.05037-11. Epub 2011 Jun 29.

33.

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A.

Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20.

34.

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.

35.

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG.

PLoS One. 2010 Oct 27;5(10):e13677. doi: 10.1371/journal.pone.0013677.

36.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.

37.

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.

Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM.

Vaccine. 2010 Oct 28;28(46):7427-35. doi: 10.1016/j.vaccine.2010.08.092. Epub 2010 Sep 17.

PMID:
20851080
38.

Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V, Frank G, Audran R, Razaname A, Nebie I, Awobusuyi O, Spertini F, Kajava AV, Felger I, Druilhe P, Corradin G.

Infect Immun. 2009 Dec;77(12):5701-9. doi: 10.1128/IAI.00652-09. Epub 2009 Sep 28.

39.

Optimized subunit vaccine protects against experimental leishmaniasis.

Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler RN, Vedvick TS, Reed SG.

Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.

40.

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.

PMID:
19679214
41.

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN.

Vaccine. 2009 May 18;27(23):3063-71. doi: 10.1016/j.vaccine.2009.03.018. Epub 2009 Mar 26.

42.

Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Goto Y, Bhatia A, Raman VS, Vidal SE, Bertholet S, Coler RN, Howard RF, Reed SG.

Vaccine. 2009 May 11;27(21):2884-90. doi: 10.1016/j.vaccine.2009.02.079. Epub 2009 Mar 9.

43.

New horizons in adjuvants for vaccine development.

Reed SG, Bertholet S, Coler RN, Friede M.

Trends Immunol. 2009 Jan;30(1):23-32. doi: 10.1016/j.it.2008.09.006. Epub 2008 Dec 6. Review.

PMID:
19059004
44.

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG.

J Immunol. 2008 Dec 1;181(11):7948-57.

45.

Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG.

Vaccine. 2007 Oct 16;25(42):7450-8. Epub 2007 Aug 20.

46.

Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear.

Duthie MS, Reece ST, Lahiri R, Goto W, Raman VS, Kaplan J, Ireton GC, Bertholet S, Gillis TP, Krahenbuhl JL, Reed SG.

Infect Immun. 2007 Nov;75(11):5290-7. Epub 2007 Aug 27.

47.

Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo.

Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, Houde M, Desjardins M, Sher A, Sacks D.

J Immunol. 2006 Sep 15;177(6):3525-33.

48.

Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL.

Infect Immun. 2005 Oct;73(10):6620-8.

49.

Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.

Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, Belkaid Y, Sacks DL.

Infect Immun. 2005 Aug;73(8):4714-22.

50.

Impairment of Brucella growth in human macrophagic cells that produce nitric oxide.

Gross A, Bertholet S, Mauel J, Dornand J.

Microb Pathog. 2004 Feb;36(2):75-82.

PMID:
14687560

Supplemental Content

Loading ...
Support Center